Simultaneous determination of paracetamol and dextropropoxyphene in human plasma by liquid chromatography/tandem mass spectrometry: Application to clinical bioequivalence studies

Rapid Communications in Mass Spectrometry

Volumn 19, Issue 6, 2005, Pages 767-774

  Yin, Ophelia Q P ^a   Lam, Sherry S L ^a   Chow, Moses S S ^a  

^a Prince of Wales Hospital   (Hong Kong)

Author keywords

[No Author keywords available]

Indexed keywords

COLUMN CHROMATOGRAPHY; DRUG PRODUCTS; LIQUID CHROMATOGRAPHY; PHASE SEPARATION; PLASMA (HUMAN);

BIOEQUIVALENCE STUDY; DEXTROPROPOXYPHENE; HUMAN PLASMAS; INTERNAL STANDARDS; LIQUID CHROMATOGRAPHY - MASS SPECTROMETRIES; LIQUID CHROMATOGRAPHY-TANDEM MASS SPECTROMETRY; LIQUID CHROMATOGRAPHY/TANDEM MASS SPECTROMETRY; PARACETAMOL; SIMULTANEOUS DETERMINATIONS; SOLID-PHASE EXTRACTION;

MASS SPECTROMETRY;

ACETIC ACID; ACETONITRILE; DEXTROPROPOXYPHENE; DEXTROPROPOXYPHENE PLUS PARACETAMOL; DRUG; GENAGESIC; PARACETAMOL; PYRROLIFENE; TOLBUTAMIDE; UNCLASSIFIED DRUG; WATER;

ACCURACY; AREA UNDER THE CURVE; ARTICLE; BIOEQUIVALENCE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG HALF LIFE; DRUG MIXTURE; DRUG STABILITY; DRUG STRUCTURE; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; LIQUID CHROMATOGRAPHY; NORMAL HUMAN; QUALITY CONTROL; SINGLE DRUG DOSE; SOLID PHASE EXTRACTION; TABLET; TANDEM MASS SPECTROMETRY;

EID: 14844290281     PISSN: 09514198     EISSN: None     Source Type: Journal    
DOI: 10.1002/rcm.1850     Document Type: Article

References (24)

1. Wan PAL, Zhang WY. Br. Med. J. 1997; 315: 1565.
2. Hanks GW, Forbes K. Br. Med. J. 1998; 316: 1980.
3. Heitmeier S, Blaschke G. J. Chromatogr. 1999; 721: 93.
4. Matsumoto T, Sano T, Matsuoka T, Aoki M, Maeno Y, Nagao M. J. Anal. Toxicol. 2003; 27: 118.
5. Knox JH, Jurand J. J. Chromatogr. 1978; 149: 297.
6. Colin P, Sirois G, Chakrabarti S. J. Chromatogr. 1987; 413: 151.
7. Rustum AM. J. Chromatogr. Sci. 1989; 27: 18.
8. Brunner LJ, Bai S. J. Chromatogr. 1999; 732: 323.
9. Al-Obaidy SS, Po ALW, McKienan DJ, Glasgow JFT, Millership J. J. Pharmaceut. Biomed. Anal. 1995; 13: 1033.
10. Jensen LS, Valentine J, Milne RW, Evans AM. J. Pharmaceut. Biomed. Anal. 2004; 34: 585.
11. Pettersson KJ, Nilsson LB. J. Chromatogr. 1992; 581: 161.
12. Kunka RL, Yong CL, Ladik CF, Bates TR. J. Pharm. Sci. 1985; 74: 103.
13. Flanagan RJ, Ramsay JD, Jane I. Hum. Toxicol. 1984; 3: 103S.
14. Kinney CD, Kelly JG. J. Chromatogr. 1987; 419: 433.
15. Shin H, Lho D, Park J. J. Chromatogr. 1989; 491: 448.
16. Gaillard Y, Pepin G. J. Chromatogr. 1998; 709: 69.
17. Amalfitano G, Bessard J, Vincent F, Eysseric H, Bessard G. J. Anal. Toxicol. 1996; 20: 547.
18. Lakso HA, Norstrom A. J. Chromatogr. 2003; 794: 57.
19. US Department of Health and Human Services Food and Drug Administration, Guidance for Industry: Bioavailability and bioequivalence studies for orally administered drug products-general considerations. US Department of Health and Human Services: Rockville, MD, 2002.
20. Hawton K, Simkin S, Deeks J. Br. Med. J. 2003; 326: 1006.
21. US Department of Health and Human Services Food and Drug Administration, Guidance for Industry: Bioanalytical Method validation. US Department of Health and Human Services, Rockville, MD, 2001.
22. Di Girolamo A, O'Neil WM, Wainer IW. J. Pharmaceut. Biomed. Anal. 1998; 17: 1191.
23. Yin OQP, Tomlinson B, Chow AHL, Chow MSS. Int. J. Pharm. 2001; 222: 305.
24. Flanagan RJ, Johnston A, White AST, Crome P. Br. J. Clin. Pharmacol. 1989; 28: 463.